Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Sutro Biopharma (STRO) Net Income towards Common Stockholders (2017 - 2025)

Historic Net Income towards Common Stockholders for Sutro Biopharma (STRO) over the last 9 years, with Q3 2025 value amounting to -$56.9 million.

  • Sutro Biopharma's Net Income towards Common Stockholders fell 1654.13% to -$56.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$206.2 million, marking a year-over-year decrease of 6631.12%. This contributed to the annual value of -$227.5 million for FY2024, which is 11301.11% down from last year.
  • According to the latest figures from Q3 2025, Sutro Biopharma's Net Income towards Common Stockholders is -$56.9 million, which was down 1654.13% from -$11.5 million recorded in Q2 2025.
  • Over the past 5 years, Sutro Biopharma's Net Income towards Common Stockholders peaked at $31.1 million during Q4 2023, and registered a low of -$72.5 million during Q4 2024.
  • Over the past 5 years, Sutro Biopharma's median Net Income towards Common Stockholders value was -$38.5 million (recorded in 2023), while the average stood at -$35.9 million.
  • In the last 5 years, Sutro Biopharma's Net Income towards Common Stockholders surged by 18977.57% in 2023 and then crashed by 33337.73% in 2024.
  • Sutro Biopharma's Net Income towards Common Stockholders (Quarter) stood at -$38.1 million in 2021, then increased by 9.26% to -$34.6 million in 2022, then surged by 189.78% to $31.1 million in 2023, then tumbled by 333.38% to -$72.5 million in 2024, then grew by 21.55% to -$56.9 million in 2025.
  • Its Net Income towards Common Stockholders was -$56.9 million in Q3 2025, compared to -$11.5 million in Q2 2025 and -$65.3 million in Q1 2025.